{"id":2529,"date":"2017-05-16T00:00:00","date_gmt":"2017-05-15T22:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/"},"modified":"2019-01-13T16:39:00","modified_gmt":"2019-01-13T15:39:00","slug":"16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/","title":{"rendered":"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial"},"content":{"rendered":"<p><strong>Leading cancer center to conduct NOXXON trial in metastatic colorectal and pancreas cancer patients<\/strong><\/p>\n<p><strong>Trial is part of collaboration with Mercl &amp; Co\/MSD<\/strong><\/p>\n<p><strong><br \/><\/strong><\/p>\n<p><strong>Berlin, Germany, May 16, 2017<\/strong> &#8211; NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, today announced the signing of an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg under which the NCT will conduct a trial evaluating NOXXON\u2019s lead product candidate NOX-A12 in combination with Keytruda\u00ae (pembrolizumab) in metastatic pancreatic and colorectal cancer. In some preclinical studies, NOX-A12 has shown an ability to make the immediate area surrounding a model tumor, the so-called tumor microenvironment, more accessible to the immune system. The ability of many tumors to use the tumor microenvironment to hide from the immune system is believed to contribute to the insensitivity of some tumors towards checkpoint inhibitors, such as Keytruda\u00ae.<\/p>\n<p>The NCT is a leading center for cancer research and treatment, located in Heidelberg, Germany. It was jointly founded by the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Medical Faculty Heidelberg and German Cancer Aid (Deutsche Krebshilfe) in 2004 to conduct interdisciplinary research for preventing and treating cancer to ultimately benefit patients.<\/p>\n<p>The NCT investigators leading the clinical trial include Prof. Dr. Dirk J\u00e4ger, Managing Director, head of the clinical and tumor immunology research groups, and Dr. Niels Halama, Group Leader, both recognized leaders in clinical cancer research with significant experience in studying the tumor microenvironment in a clinical setting. Throughout his career, Prof. Dr. J\u00e4ger has focused on tumor and immunology as well as the interdisciplinary connections between both fields, both scientifically and clinically.<\/p>\n<p>NOXXON\u2019s Chief Medical Officer, Dr. Jarl Ulf Jungnelius, commented: \u201cDr. J\u00e4ger and Dr. Halama are experts in the treatment of metastatic cancer patients as well as the tumor microenvironment. We are extremely pleased that they will be collaborating with NOXXON on this groundbreaking study.\u201d<\/p>\n<p>Prof. Dr. J\u00e4ger, Managing Director of the NCT Heidelberg, commented: \u201cThis trial will enable us to explore the potential of NOX-A12 in combination with Keytruda\u00ae to benefit patients with few viable treatment options. Importantly, the trial will help us to better understand the ability of NOX-A12 to modify the tumor microenvironment and make it more accessible to the immune system to facilitate tumor destruction.\u201d<\/p>\n<p>\u2003<br \/>For more information, please contact:<\/p>\n<p>NOXXON Pharma N.V.<br \/>Aram Mangasarian, Ph.D., Chief Executive Officer<br \/>Tel. +49 (0) 30 726 2470<br \/><a href=\"mailto:amangasarian@noxxon.com\">amangasarian@noxxon.com<\/a><\/p>\n<p>NewCap<br \/>Florent Alba<br \/>Tel. +33 (0) 1 44 71 98 55<br \/><a href=\"mailto:falba@newcap.fr\">falba@newcap.fr<\/a><\/p>\n<p><strong>About the National Center for Tumor Diseases (NCT) Heidelberg<\/strong><\/p>\n<p>The NCT Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT&#8217;s goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2529\" data-postid=\"2529\" class=\"themify_builder_content themify_builder_content-2529 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->\n","protected":false},"excerpt":{"rendered":"<p>NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-15T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:39:00+00:00\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial\",\"datePublished\":\"2017-05-15T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\"},\"wordCount\":574,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\",\"url\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\",\"name\":\"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2017-05-15T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:39:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON announces first patients treated in phase I\/II clinical trial of NOX-A12 combined with KEYTRUDA\u00ae in metastatic pancreatic and colorectal cancer","og_url":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2017-05-15T22:00:00+00:00","article_modified_time":"2019-01-13T15:39:00+00:00","author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial","datePublished":"2017-05-15T22:00:00+00:00","dateModified":"2019-01-13T15:39:00+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/"},"wordCount":574,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/","url":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/","name":"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2017-05-15T22:00:00+00:00","dateModified":"2019-01-13T15:39:00+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/16-05-17-noxxon-pharma-announces-collaboration-with-national-center-for-tumor-diseases-in-heidelberg-for-nox-a12-keytruda-phase-1-2-combination-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12\/KEYTRUDA\u00ae Phase 1\/2 combination trial"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2529"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2529"}],"version-history":[{"count":1,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2529\/revisions"}],"predecessor-version":[{"id":2648,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2529\/revisions\/2648"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}